Lipin in hypoxic conditions: from experiment to clinic (review)

Abstract

The aim of the review was generalization and systematization of experimental and clinical data regarding the pharmacological properties and scope of Lipin (phosphatidylcholine liposomes) in conditions accompanied by hypoxia., including substantiating the feasibility of its use in the Covid-19 treatment in severe cases and respiratory failure.
Lipin using in both hypoxia and conditions where it is one of the damaging factors, is accounted for Lipin ability to retain and restore the pulmonary surfactant, to prevent damage of the aerohematical barrier structure and dissemination of inflammatory processes in lungs, to increase oxygen diffusion into blood and tissues, to prevent acidosis development of to normalize the processes of tissue respiration. Lipin helps to stabilize membranes of cells and intracellular organelles, and it is critical for preserving the structure and function of mitochondria. In addition, Lipin prevents the reduction of ATP levels and the total energy charge of the cell, thereby helping to maintain a balance between the available energy resources and the body activity.
The effectiveness of Lipin as an antihypoxic agent is confirmed in conditions with hypoxia to be the main damaging factor, such as neonatal asphyxia, placental dysfunction, acute renal failure, burn disease, pneumonia of different genesis, skeletal polytrauma, prolonged crushing syndrome, chronic obstructive pulmonary disease and so on.